Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Caution With Routine Use of Daratumumab for Newly Diagnosed High-Risk Multiple Myeloma—Reply

Caution With Routine Use of Daratumumab for Newly Diagnosed High-Risk Multiple Myeloma—Reply Letters Corresponding Author: Srikala S. Sridhar, MD, MSc, Princess Margaret Cancer the results of this meta-analysis will be used to justify rou- Centre, University Health Network, 610 University Ave, 7-625 OPG, Toronto, tine up-front use of daratumumab for newly diagnosed HRMM ON, Canada, M5G 2M9 (srikala.sridhar@uhn.ca). without confirmatory evidence. This will result in additional Published Online: February 11, 2021. doi:10.1001/jamaoncol.2020.8017 costs and toxic effects to patients for an uncertain long-term Conflict of Interest Disclosures: Dr Sridhar reported receiving grants and benefit. As the results of the recent SWOG 1211 study show, personal fees from Merck, Roche, Pfizer, AstraZeneca, Bristol Myers Squibb, one cannot simply assume that the addition of a fourth drug Janssen, and Bayer outside the submitted work. No other disclosures were reported. to a 3-drug regimen in the newly diagnosed, high-risk disease 1. Sridhar SS, Blais N, Tran B, et al. Efficacy and safety of nab-paclitaxel vs setting will benefit patients. Even if it offers a progression- paclitaxel on survival in patients With platinum-refractory metastatic urothelial free survival benefit, one cannot know whether the overall tra- cancer: the Canadian Cancer Trials Group BL.12 randomized clinical trial. JAMA jectory of the disease is changed by introducing it earlier http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png JAMA Oncology American Medical Association

Caution With Routine Use of Daratumumab for Newly Diagnosed High-Risk Multiple Myeloma—Reply

JAMA Oncology , Volume 7 (4) – Apr 18, 2021

Loading next page...
 
/lp/american-medical-association/caution-with-routine-use-of-daratumumab-for-newly-diagnosed-high-risk-m1d7fzJIL3

References (6)

Publisher
American Medical Association
Copyright
Copyright 2021 American Medical Association. All Rights Reserved.
ISSN
2374-2437
eISSN
2374-2445
DOI
10.1001/jamaoncol.2020.8020
Publisher site
See Article on Publisher Site

Abstract

Letters Corresponding Author: Srikala S. Sridhar, MD, MSc, Princess Margaret Cancer the results of this meta-analysis will be used to justify rou- Centre, University Health Network, 610 University Ave, 7-625 OPG, Toronto, tine up-front use of daratumumab for newly diagnosed HRMM ON, Canada, M5G 2M9 (srikala.sridhar@uhn.ca). without confirmatory evidence. This will result in additional Published Online: February 11, 2021. doi:10.1001/jamaoncol.2020.8017 costs and toxic effects to patients for an uncertain long-term Conflict of Interest Disclosures: Dr Sridhar reported receiving grants and benefit. As the results of the recent SWOG 1211 study show, personal fees from Merck, Roche, Pfizer, AstraZeneca, Bristol Myers Squibb, one cannot simply assume that the addition of a fourth drug Janssen, and Bayer outside the submitted work. No other disclosures were reported. to a 3-drug regimen in the newly diagnosed, high-risk disease 1. Sridhar SS, Blais N, Tran B, et al. Efficacy and safety of nab-paclitaxel vs setting will benefit patients. Even if it offers a progression- paclitaxel on survival in patients With platinum-refractory metastatic urothelial free survival benefit, one cannot know whether the overall tra- cancer: the Canadian Cancer Trials Group BL.12 randomized clinical trial. JAMA jectory of the disease is changed by introducing it earlier

Journal

JAMA OncologyAmerican Medical Association

Published: Apr 18, 2021

There are no references for this article.